BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced the initial results from the pilot section of its ongoing acetaminophen comparison study. The study, which is expected to be complete during early November, compares the effects of ActiPatch® Therapy to acetaminophen in the form of Extra Strength Tylenol® for the treatment of delayed onset muscle soreness (DOMS).

Participants in the pilot section of the study were randomly assigned to one of three groups, 1) a control group, 2) a group that used ActiPatch, and 3) a group that was treated with over-the-counter strength acetaminophen in the form of Extra Strength Tylenol. Each of the group's participants then evaluated their levels of muscle soreness and discomfort 48 hours after vigorous resistance training designed to induce delayed onset muscle soreness.

"Thus far, results from the pilot section of this study seem to be highly statistically significant with the ActiPatch group scoring its average level of muscle soreness and discomfort at much lower levels compared to either the control group or the acetaminophen treatment group," commented principal investigator Sheena Kong, M.D. "For many years physicians, medical researchers and sports trainers attributed this type of muscle soreness to the build up of lactate in muscle tissues after exercise. A significant body of research now shows delayed onset muscle soreness is mainly attributable to damage to the muscle cell membrane, which sets off an inflammatory response leading to the formation of metabolic waste products that act as a chemical stimulus to the nerve endings that directly cause the pain that is experienced after muscle over exertion. While additional research needs to be conducted on the actual mechanism, it appears ActiPatch works to reduce this inflammatory response resulting in a reduction in the formation of metabolic waste products and therefore, what appears, based on these preliminary results, to be a significant reduction in levels of muscle pain and soreness."

The study, which is Institutional Review Board (IRB) supervised, is currently ongoing with full study results expected during early November 2009. Principal investigator, Sheena Kong, M.D., holds no financial position in any form in the study's sponsor, BioElectronics Corporation, and will receive no financial compensation of any kind for the completion of the study.

Source
BioElectronics Corporation